The emerging quest for the optimal angiostatic combination therapy

Biochemical Society Transactions

Volumn 42, Issue 6, 2014, Pages 1608-1615

  Griffioen, Arjan W ^a   Weiss, Andrea ^a,b   Berndsen, Robert H ^a,b   Abdul, U Kulsoom ^a   Te Winkel, Marije T ^a   Nowak Sliwinska, Patrycja ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EPFL   (Switzerland)

Author keywords

Chemotherapy; Combination therapy; Immunotherapy; ngiogenesis; Photodynamic therapy; Radiotherapy; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; DRUG COMBINATION; IMMUNOTHERAPY; NEOPLASMS; PHOTOCHEMOTHERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PHOTOCHEMOTHERAPY;

EID: 84911890466     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140193     Document Type: Review

References (74)

1. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 CrossRef PubMed
2. Demetri, G.D., van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij, J., McArthur, G., Judson, I.R., Heinrich, M.C., Morgan, J.A. et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 CrossRef PubMed
3. Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Wilding, G., Figlin, R.A., Ginsberg, M.S., Kim, S.T., Baum, C.M., DePrimo, S.E. et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 CrossRef PubMed
4. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R. et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 CrossRef PubMed
5. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 CrossRef PubMed
6. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G. et al. (2012) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17, 7337-7346 CrossRef
7. Griffioen, A.W. and Molema, G. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52, 237-268 PubMed
8. Carmeliet, P. and Jain, R.K. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 CrossRef PubMed
9. Fan, F., Samuel, S., Gaur, P., Lu, J., Dallas, N.A., Xia, L., Bose, D., Ramachandran, V. and Ellis, L.M. (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br. J. Cancer 104, 1270-1277 CrossRef PubMed
10. Dorrell, M.I., Aguilar, E., Scheppke, L., Barnett, F.H. and Friedlander, M. (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 104, 967-972 CrossRef PubMed
11. Albiges, L., Choueiri, T., Escudier, B., Galsky, M., George, D., Hofmann, F., Lam, T., Motzer, R., Mulders, P., Porta, C. et al. (2014) A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur. Urol., doi:10.1016/j.eururo.2014.04.006 PubMed
12. Yokoyama, Y., Dhanabal, M., Griffioen, A.W., Sukhatme, V.P. and Ramakrishnan, S. (2000) Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60, 2190-2196 PubMed
13. Dings, R.P., Yokoyama, Y., Ramakrishnan, S., Griffioen, A.W. and Mayo, K.H. (2003) The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 63, 382-385 PubMed
14. Faris, J.E. and Michaelson, M.D. (2010) Targeted therapies: sunitinib versus interferon-α in metastatic RCC. Nat. Rev. Clin. Oncol. 7, 7-8 CrossRef PubMed
15. Rini, B.I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A.G., Hariharan, S. and Escudier, B. (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752-759 CrossRef PubMed
16. Rini, B.I., Garcia, J.A., Cooney, M.M., Elson, P., Tyler, A., Beatty, K., Bokar, J., Mekhail, T., Bukowski, R.M., Budd, G.T. et al. (2009) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 15, 6277-6283 CrossRef PubMed
17. Rini, B.I., Garcia, J.A., Cooney, M.M., Elson, P., Tyler, A., Beatty, K., Bokar, J., Ivy, P., Chen, H.X., Dowlati, A. and Dreicer, R. (2010) Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J. Clin. Oncol. 28, e284-e285 CrossRef PubMed
18. Grellety, T., Brugeres-Chakiba, C., Chaminade, A., Roubaud, G., Ravaud, A. and Gross-Goupil, M. (2014) Revision of therapeutic index for targeted treatment in kidney cancer: what if toxicity could predict efficacy? Bull. Cancer 101, 608-618 PubMed
19. Klauber, N., Parangi, S., Flynn, E., Hamel, E. and D'Amato, R.J. (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57, 81-86 PubMed
20. Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S. and Folkman, J. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 PubMed
21. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P. and Kerbel, R.S. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 CrossRef PubMed
22. Kleibeuker, E.A., Griffioen, A.W., Verheul, H.M., Slotman, B.J. and Thijssen, V.L. (2012) Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist. Updat. 15, 173-182 CrossRef PubMed
23. Nowak-Sliwinska, P., van Beijnum, J.R., van Berkel, M., van den Bergh, H. and Griffioen, A.W. (2010) Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 13, 281-292 CrossRef PubMed
24. Dings, R.P., Vang, K.B., Castermans, K., Popescu, F., Zhang, Y., Oude Egbrink, M.G., Mescher, M.F., Farrar, M.A., Griffioen, A.W. and Mayo, K.H. (2011) Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin. Cancer Res. 17, 3134-3145 CrossRef PubMed
25. Andre, N., Carre, M. and Pasquier, E. (2014) Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413-431 CrossRef PubMed
26. Rademaker-Lakhai, J.M., van den Bongard, D., Pluim, D., Beijnen, J.H. and Schellens, J.H. (2004) A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10, 3717-3727 CrossRef PubMed
27. Hartinger, C.G., Jakupec, M.A., Zorbas-Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P.J. and Keppler, B.K. (2008) KP1019, a new redox-active anticancer agent: preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodivers. 5, 2140-2155 CrossRef PubMed
28. Hashimoto, K., Man, S., Xu, P., Cruz-Munoz, W., Tang, T., Kumar, R. and Kerbel, R.S. (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996-1006 CrossRef PubMed
29. Tran Cao, H.S., Bouvet, M., Kaushal, S., Keleman, A., Romney, E., Kim, G., Fruehauf, J., Imagawa, D.K., Hoffman, R.M. and Katz, M.H. (2010) Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol. Cancer Ther. 9, 2068-2078 CrossRef PubMed
30. Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Korner, W., Jungwirth, U., Mohr, T., Keppler, B.K. and Berger, W. (2013) The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur. J. Cancer 49, 3366-3375 CrossRef PubMed
31. Montagna, E., Cancello, G., Bagnardi, V., Pastrello, D., Dellapasqua, S., Perri, G., Viale, G., Veronesi, P., Luini, A., Intra, M. et al. (2012) Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin. Breast Cancer 12, 207-214 CrossRef PubMed
32. Saloustros, E., Kalbakis, K., Vardakis, N., Kalykaki, A., Milaki, G., Rovithi, M., Agelaki, S., Saridaki, Z., Georgoulias, V. and Mavroudis, D. (2011) Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J. Buon. 16, 215-218 PubMed
33. Garcia, A.A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D.D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D. et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26, 76-82 CrossRef PubMed
34. Eichbaum, M., Mayer, C., Eickhoff, R., Bischofs, E., Gebauer, G., Fehm, T., Lenz, F., Fricke, H.C., Solomayer, E., Fersis, N. et al. (2011) The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 11, 453 CrossRef PubMed
35. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., Kozak, K.R., Cahill, D.P., Chen, P.J., Zhu, M. et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 CrossRef PubMed
36. Dings, R.P., Loren, M., Heun, H., McNiel, E., Griffioen, A.W., Mayo, K.H. and Griffin, R.J. (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395-3402 CrossRef PubMed
37. Gasparini, G., Torino, F., Ueno, T., Cascinu, S., Troiani, T., Ballestrero, A., Berardi, R., Shishido, J., Yoshizawa, A., Mori, Y., Nagayama, S., Morosini, P. and Toi, M. (2012) A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 15, 141-150 CrossRef PubMed
38. Sofia Vala, I., Martins, L.R., Imaizumi, N., Nunes, R.J., Rino, J., Kuonen, F., Carvalho, L.M., Ruegg, C., Grillo, I.M., Barata, J.T., Mareel, M. and Santos, S.C. (2010) Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS ONE 5, e11222 CrossRef PubMed
39. Hlushchuk, R., Riesterer, O., Baum, O., Wood, J., Gruber, G., Pruschy, M. and Djonov, V. (2008) Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am. J. Pathol. 173, 1173-1185 CrossRef PubMed
40. Seiwert, T.Y., Haraf, D.J., Cohen, E.E., Stenson, K., Witt, M.E., Dekker, A., Kocherginsky, M., Weichselbaum, R.R., Chen, H.X. and Vokes, E.E. (2008) Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol. 26, 1732-1741 CrossRef PubMed
41. Czito, B.G., Bendell, J.C., Willett, C.G., Morse, M.A., Blobe, G.C., Tyler, D.S., Thomas, J., Ludwig, K.A., Mantyh, C.R., Ashton, J., Yu, D. and Hurwitz, H.I. (2007) Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int. J. Radiat. Oncol. Biol. Phys. 68, 472-478 CrossRef PubMed
42. Knisely, J.P., Berkey, B., Chakravarti, A., Yung, A.W., Curran, W.J. Jr., Robins, H.I., Movsas, B., Brachman, D.G., Henderson, R.H. and Mehta, M.P. (2008) A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int. J. Radiat Oncol. Biol. Phys. 71, 79-86 CrossRef PubMed
43. Sakkoula, E., Pipili-Synetos, E. and Maragoudakis, M.E. (1997) Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br. J. Pharmacol. 122, 793-795 CrossRef PubMed
44. Gutbrodt, K.L., Schliemann, C., Giovannoni, L., Frey, K., Pabst, T., Klapper, W., Berdel, W.E. and Neri, D. (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci. Transl. Med. 5, 201ra118 CrossRef PubMed
45. Hemmerle, T. and Neri, D. (2014) The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int. J. Cancer 134, 467-477 CrossRef PubMed
46. Coughlin, C.M., Salhany, K.E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A.E., Hunter, C.A., Fox, J.C., Trinchieri, G. and Lee, W.M. (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441-1452 CrossRef PubMed
47. Rodriguez-Galan, M.C., Reynolds, D., Correa, S.G., Iribarren, P., Watanabe, M. and Young, H.A. (2009) Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J. Immunol. 183, 740-748 CrossRef PubMed
48. Brivio, F., Lissoni, P., Rovelli, F., Nespoli, A., Uggeri, F., Fumagalli, L. and Gardani, G. (2002) Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49, 385-387 PubMed
49. Castermans, K., Tabruyn, S.P., Zeng, R., van Beijnum, J.R., Eppolito, C., Leonard, W.J., Shrikant, P.A. and Griffioen, A.W. (2008) Angiostatic activity of the antitumor cytokine interleukin-21. Blood 112, 4940-4947 CrossRef PubMed
50. Dehne, N., Tausendschon, M., Essler, S., Geis, T., Schmid, T. and Brune, B. (2014) IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1α translation. J. Leukoc. Biol. 95, 129-137 CrossRef PubMed
51. Albini, A., Brigati, C., Ventura, A., Lorusso, G., Pinter, M., Morini, M., Mancino, A., Sica, A. and Noonan, D.M. (2009) Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J. Transl. Med. 7, 5 CrossRef PubMed
52. Raig, E.T., Jones, N.B., Varker, K.A., Benniger, K., Go, M.R., Biber, J.L., Lesinski, G.B. and Carson, III, W.E. (2008) VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J. Interferon Cytokine Res. 28, 553-561 CrossRef PubMed
53. McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., Logan, T.F., Kirkwood, J.M., Gordon, M.S., Sosman, J.A., Ernstoff, M.S. et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 CrossRef PubMed
54. Eisenbeis, C.F., Lesinski, G.B., Anghelina, M., Parihar, R., Valentino, D., Liu, J., Nadella, P., Sundaram, P., Young, D.C., Sznol, M., Walker, M.J. and Carson, III, W.E. (2005) Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J. Clin. Oncol. 23, 8835-8844 CrossRef PubMed
55. Gollob, J.A., Veenstra, K.G., Parker, R.A., Mier, J.W., McDermott, D.F., Clancy, D., Tutin, L., Koon, H. and Atkins, M.B. (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21, 2564-2573 CrossRef PubMed
56. Petrella, T.M., Tozer, R., Belanger, K., Savage, K.J., Wong, R., Smylie, M., Kamel-Reid, S., Tron, V., Chen, B.E., Hunder, N.N. et al. (2012) Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J. Clin. Oncol. 30, 3396-3401 CrossRef PubMed
57. Agostinis, P., Berg, K., Cengel, K.A., Foster, T.H., Girotti, A.W., Gollnick, S.O., Hahn, S.M., Hamblin, M.R., Juzeniene, A., Kessel, D. et al. (2011) Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61, 250-281 CrossRef PubMed
58. Babilas, P., Schreml, S., Landthaler, M. and Szeimies, R.M. (2010) Photodynamic therapy in dermatology: state-of-the-art. Photodermatol. Photoimmunol. Photomed. 26, 118-132 CrossRef PubMed
59. Savary, J.F., Grosjean, P., Monnier, P., Fontolliet, C., Wagnieres, G., Braichotte, D. and van den Bergh, H. (1998) Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. Endoscopy 30, 258-265 CrossRef PubMed
60. Rumie Vittar, N.B., Lamberti, M.J., Pansa, M.F., Vera, R.E., Rodriguez, M.E., Cogno, I.S., Milla Sanabria, L.N. and Rivarola, V.A. (2013) Ecological photodynamic therapy: new trend to disrupt the intricate networks within tumor ecosystem. Biochim. Biophys. Acta 1835, 86-99 PubMed
61. Weiss, A., den Bergh, H., Griffioen, A.W. and Nowak-Sliwinska, P. (2012) Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. Biochim. Biophys. Acta 1826, 53-70 PubMed
62. Nowak-Sliwinska, P., Weiss, A., Sickenberg, M., Griffioen, A. and Van den Bergh, H. (2013) The role of photodynamic therapy in non-malignant eye disorders. J. Anal. Bioanal. Tech. 15, 1-25
63. Nowak-Sliwinska, P., van den Bergh, H., Sickenberg, M. and Koh, A.H. (2013) Photodynamic therapy for polypoidal choroidal vasculopathy. Prog. Retin. Eye Res. 37, 182-199 CrossRef PubMed
64. Nowak-Sliwinska, P. (2012) Anti-angiogenic treatment for exudative age-related macular degeneration. Curr. Angiogenesis 1, 318-334
65. Hsu, C.C., Yang, C.S., Peng, C.H., Lee, F.L. and Lee, S.M. (2011) Combination photodynamic therapy and intravitreal bevacizumab used to treat circumscribed choroidal hemangioma. J. Chin. Med. Assoc. 74, 473-477 CrossRef PubMed
66. Guyon, L., Ascencio, M., Collinet, P. and Mordon, S. (2012) Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagnosis Photodyn. Ther. 9, 16-31 CrossRef PubMed
67. Piatrouskaya, N.A., Kharuzhyk, S.A., Vozmitel, M.A., Mazurenko, A.N. and Istomin, Y.P. (2010) Experimental study of antiangiogenic and photodynamic therapies combination for treatment of peritoneal carcinomatosis: preliminary results. Exp. Oncol. 32, 100-103 PubMed
68. Nowak-Sliwinska, P., Weiss, A., van Beijnum, J.R., Wong, T.J., Ballini, J.P., Lovisa, B., van den Bergh, H. and Griffioen, A.W. (2012) Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J. Cell. Mol. Med. 16, 1553-1562 CrossRef PubMed
69. Weiss, A., van Beijnum, J.R., Bonvin, D., Jichlinski, P., Dyson, P.J., Griffioen, A.W. and Nowak-Sliwinska, P. (2014) Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J. Cell. Mol. Med. 18, 480-491 CrossRef PubMed
70. Ferrario, A. and Gomer, C.J. (2006) Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J. Environ. Pathol. Toxicol. Oncol. 25, 251-259 CrossRef PubMed
71. Gamal-Eldeen, A.M., El-Daly, S.M., Borai, I.H., Wafay, H.A. and Abdel-Ghaffar, A.R. (2013) Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice. Photodiagnosis Photodyn. Ther. 10, 446-459 CrossRef PubMed
72. Gamaleia, N.F., Lisnyak, I.A., Shishko, E.D., Mamchur, A.A., Prokopenko, I.V. and Kholin, V.V. (2012) Chronobiological approaches to antiangiogenic photodynamic therapy of tumors: the first experimental evaluation. Exp. Oncol. 34, 364-366 PubMed
73. Schattler, H., Ledzewicz, U. and Cardwell, B. (2011) Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis. Math. Biosci. Eng. 8, 355-369 CrossRef PubMed
74. Kohandel, M., Haselwandter, C.A., Kardar, M., Sengupta, S. and Sivaloganathan, S. (2011) Quantitative model for efficient temporal targeting of tumor cells and neovasculature. Comput. Math. Methods Med. 2011, 790721 CrossRef PubMed